Be Aware of SGLT2 Inhibitor Risks
SGLT2 inhibitor (empagliflozin, etc) risks will be back in the spotlight...due to recent label changes.
These meds are getting more use now that most have proven CV benefits...despite usually costing about $500/month.
Be familiar with how to manage SGLT2 inhibitor risks.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote